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Background:  Dengue  virus  (DENV)  infection  remains  a major  public  health  burden  worldwide.  Soluble
mediators  may  play  a  critical  role  in  the pathogenesis  of acute  DENV  infection.  Galectin-9  (Gal-9)  is a
soluble  -galactoside-binding  lectin,  with  multiple  immunoregulatory  and  inﬂammatory  properties.
Objective:  To investigate  plasma  Gal-9  levels  as  a  biomarker  for DENV  infection.
Study  design:  We  enrolled  65  DENV  infected  patients  during  the  2010  epidemic  in  the  Philippines  and
measured  their  plasma  Gal-9 and  cytokine/chemokine  levels,  DENV  genotypes,  and  copy  number  during
the critical  and  recovery  phases  of  illness.
Results:  During  the critical  phase,  Gal-9  levels  were  signiﬁcantly  higher  in  DENV  infected  patients  com-
pared to  healthy  or those  with  non-dengue  febrile  illness.  The highest  Gal-9  levels  were  observed  in
dengue  hemorrhagic  fever (DHF)  patients  (DHF:  2464  pg/ml;  dengue  fever  patients  (DF):  1407  pg/ml;
non-dengue  febrile  illness:  616 pg/ml;  healthy:  196  pg/ml).  In the  recovery  phase,  Gal-9  levels  signif-
icantly  declined  from  peak  levels  in  DF  and  DHF  patients.  Gal-9 levels  tracked  viral  load,  and  were
associated  with  multiple  cytokines  and  chemokines  (IL-1,  IL-8, IP-10,  and  VEGF),  including  monocyte
frequencies  and  hematologic  variables  of  coagulation.  Further  discriminant  analyses  showed  that  eotaxin,
Gal-9, IFN-2,  and  MCP-1  could  detect  92%  of DHF  and  79.3%  of  DF,  speciﬁcally  (P  <  0.01).
Conclusion:  Gal-9  appears  to track DENV  inﬂammatory  responses,  and therefore,  it could  serve  as  an
important  novel  biomarker  of acute  DENV  infection  and disease  severity.
 201©
. BackgroundDengue is caused by the dengue virus (DENV), which
elongs to the family Flaviviridae, genus Flavivirus,  and is now
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emerging as one of the most rapidly spreading mosquito-borne
viral diseases worldwide.1,2 DENV has an incubation period of
3–7 days, where after the symptoms suddenly appear. Clini-
cally, the onset of symptoms is rapid and follows 3 distinct
phases: (1) an initial febrile phase on days 1–3 of illness; (2)
a critical phase on days 4–6 of illness, which coincides with
defervescence; and (3) a spontaneous recovery phase on days
7–10 of illness. Dengue fever (DF) is accompanied by a high
fever, headaches, severe myalgia, and rash. Severe DENV infec-
Open access under CC BY-NC-ND license.tion complications can occur resulting in dengue hemorrhagic
fever (DHF), which is characterized with clinical and labora-
tory features of thrombocytopenia, coagulation abnormalities,
and plasma leakage in children and worse outcomes in adults
icense.
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resenting with increased incidences of bleeding, shock and organ
ailure.3,4
It is thought that following acute DENV infection, the high
iral load triggers an activated immunological state, resulting in
he release of inﬂammatory cytokines, chemokines, immune com-
lexes, and other inﬂammatory mediators.5 During the evolution
f DENV infection, both pro-inﬂammatory and anti-inﬂammatory
ytokines and chemokines are induced, suggesting that multifacto-
ial mediators are also involved in DENV-induced pathogenesis.6–8
Galectins constitute a family of mammalian lectins that have
n afﬁnity for -galactoside. These proteins are released into the
xtra-cellular environment under stress conditions such as infec-
ious, during which they serve as “danger signals” or exert their
ctions on other cells.9 Galectin-9 (Gal-9) was ﬁrst described as an
osinophilic chemoattractant.10,11 Since then, Gal-9 is reported to
e produced by both T and endothelial cells,12,13 and its functions
s a bidirectional immunoregulator was recently described.14,15
e  previously described increases in Gal-9 and histamine levels
n an allergic patient and suggested that the activation of mast cells
s associated with elevation in Gal-9 levels.16 We  also reported a
arked elevation of Gal-9 in acute human immunodeﬁciency virus
HIV) infection and a rapid decrease after anti-retroviral therapy,
nd our data from that study suggested that Gal-9 could be a poten-
ial danger signal biomarker of acute virus infection.17,18
. Objectives
To examine the kinetics and activities of Gal-9 in DENV infection
nd its association with other circulating plasma mediators during
he course of acute DENV infection.
. Study design
.1. Patients and specimens
We  conducted a study at the San Lazaro Hospital in Manila,
hilippines, which included 65 serially recruited patients with a
linical diagnosis of DF and DHF.19 In 2010, there were consecutive
ases of dengue in this hospital, and we enrolled patients who met
he study’s inclusion criteria. None of the patients included in our
tudy died, and all of them were discharged from the hospital when
heir condition improved. EDTA plasma and serum were obtained
y centrifugation of peripheral blood at 3000 rpm for 10 min, and
ere aliquoted into 1.2 ml  micro tubes and stored at −80 ◦C until
se. Specimens were collected at 2 time points during illness of
he critical phase (on days 4–5) and the recovery phase (on days
–8). All enrolled patients underwent laboratory tests, their medi-
al histories were recorded, and they were physically examined by
esident clinicians. Plasma was also obtained from 30 demograph-
cally matched healthy controls (HCs). HCs were donors who came
o the Hospital for annual health checks or who volunteered at the
ospital. In addition, 90 patients with non-dengue febrile illness,
ho had visited San Lazaro Hospital, were enrolled. These patients
ere clinically diagnosed with leptospirosis, conﬁrmed by serolog-
cal analysis and/or microscopic agglutination test.20 Plasma from
atients with non-dengue febrile illness was collected at the time
f admission.
.2. Serological analysisPrimary and secondary DENV infections were conﬁrmed by
etermining antiviral IgM and/or IgG antibodies levels using sera
The Panbio Duo Dengue IgM and IgG Capture enzyme-linked
mmunosorbent assay (ELISA), Panbio, Queensland, Australia).21ical Virology 58 (2013) 635– 640
3.3. RNA extraction
Genomic viral RNA was extracted from 140 l of each patient
serum (critical phase, n = 65) using the QIAamp viral RNA mini
kit (QIAGEN, Hilden, Germany). The extracted RNA was stored at
−80 ◦C until further use.
3.4. DENV genotyping
DENV genotyping was  performed by the dengue genotype-
speciﬁc reverse transcriptase loop-mediated isothermal ampliﬁ-
cation (RT-LAMP) method.22 The RT-LAMP reaction was carried
out in a 25 l reaction mixture with the use of the Loopamp RNA
Ampliﬁcation Kit (Eiken Chemical Co., Ltd., Tokyo, Japan), and it
was performed with 1 l of template RNA. The reaction mix  was
incubated at 60 ◦C for 60 min  in a Loopamp real-time turbidometer
LA-320C (Teramecs, Kyoto, Japan). Positive and negative controls
were included in each run, and all precautions to prevent cross-
contamination were taken. The results were conﬁrmed by LA-320C
software.
3.5. Real-time RT-PCR and DENV quantiﬁcation
The DENV copy number in plasma was  measured by a TaqMan®
one-step real-time RT-PCR as described previously.23 The real-time
RT-PCR primers and hydrolysis probe speciﬁc to the 3′ untrans-
lated region (UTR) of the four-dengue genotypes were described
previously.24 In this study, hydrolysis probe was labeled by FAM
at the 5′ end and BHQ-1 at the 3′ end. The real-time RT-PCR
assay was  performed using the SuperScript® III Platinum One-Step
qRT-PCR Kit (Invitrogen, USA), according to the manufacturer’s
instructions. Quantitative standard RNA or each DENV genotype
was performed using the in vitro transcription of the pCR®2.1-
TOPO® vector (Invitrogen, USA), which was cloned at the 3′ UTR for
each DENV genotype: genotype 1 (strain 99St-12A; GenBank acces-
sion no GU377286), genotype 2 (00St-22A; GU377287), genotype
3 (SLMC50; GU377288), and genotype 4 (SLMC318; GU377289),
respectively. The target RNA copy number was calculated, and
10-fold serial dilutions ranging from 102 to 105 RNA copies per
microliter were used for quantiﬁcation standards. One  microliter
of RNA standard or extracted RNA was  used as template per reac-
tion. Virus titer in each reaction was  calculated using 7500 System
Software (Applied Biosystems, USA).
3.6. Galectin-9 and cytokine/chemokines detection assay
Plasma Gal-9 was quantiﬁed by means of ELISA, as previously
described.17 Brieﬂy, the sandwich ELISA consists of anti-human
Gal-9 monoclonal antibodies (clone 9S2-3; GalPharma, Takamatsu,
Japan) and biotinylated-anti-human Gal-9 polyclonal antibodies
(GalPharma, Takamatsu, Japan) as a coating and detection anti-
bodies, respectively. Colorimetric analysis was carried out using
streptavidin-conjugated horseradish peroxidase (Thermo Fisher
Scientiﬁc, Waltham, MA,  USA) and tetramethyl benzidine (KPL,
Gaithersburg, MD,  USA). Gal-9 concentration was quantiﬁed using
a standard curve constructed with recombinant human Gal-9 (Gal-
Pharma, Takamatsu, Japan). Plasma samples were also assayed for
29 selected cytokines and chemokines (EGF, eotaxin, G-CSF, GM-
CSF, IFN-2, IFN-, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17,
IL-1ra, IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1,
MIP-1, MIP-1,  TNF-, TNF-, and VEGF) using a Milliplex Human
Cytokine and Chemokine multiplex assay Kit (Merck Millipore, Bil-
lerica, MA,  USA). The experiments were performed according to the
manufacturers’ instructions using a Luminex 200 System (Luminex
Corporation, Austin, USA).25
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Fig. 1. Plasma levels of galectin-9 in dengue virus infected individuals. (A) Signiﬁcantly different levels of plasma galectin-9 in the critical phase of patients with DF and DHF  as
well  as in non-dengue febrile illness (patients with leptospirosis) and healthy controls (Kruskal–Wallis test, P < 0.0001). Dunn’s multiple comparison tests showed signiﬁcant
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F,  dengue fever; DHF, dengue hemorrhagic fever.
.7. Statistical analysis
We  tested for differences in plasma Gal-9 levels between
roups (DF, DHF, non-dengue febrile illness, and HCs) using the
ruskal–Wallis test and between the critical and recovery phases
f DENV infection with the Wilcoxon signed-ranks test. Differ-
nces in the clinical data between patients with DF and DHF
nd cytokine/chemokine levels between patients and HCs were
ssessed by the Mann–Whitney test. These statistical analyses
ere performed using GraphPad Prism 6 software (GraphPad Soft-
are, San Diego, CA, USA). In addition, a stepwise discriminant
nalysis was used to differentiate DHF from DF patients using
al-9 and other cytokine/chemokines. Furthermore, to determine
he variables that independently associated with Gal-9 in the
ENV infected patients, a stepwise multiple regression analysis
as performed. Multivariable analyses were conducted using the
kuseru-Toukei 2012 software (Social Survey Research Information
o., Ltd., Tokyo, Japan).
. Results
.1. Basic and clinical characteristics of the acute DENV infected
atients
The mean age of the patients with DENV infection (n = 65), non-
engue febrile illness (n = 90), and HCs (n = 30) were 23.5, 33.4, and
3.7 years, respectively. All DENV infected patients had anti-DENV
gG and/or IgM. Secondary infection that was caused by preexisting
gG antibodies was conﬁrmed in 62% of the total group of patients.
econdary infection was seen in 57% and 83% of patients with DF
nd DHF, respectively. Patients with DHF had signiﬁcantly lower
latelet counts and signiﬁcantly higher Hct levels than patients
ith DF.engue febrile illness and DF/DHF. (B) No signiﬁcant differences in galectin-9 levels
 from the critical to recovery phases in patients with DF and DHF. Abbreviations:
4.2. Assessment of DENV genotype and viral RNA copy number
We identiﬁed dengue genotypes in 27 of the 65 samples (42%)
by LAMP methods. Amongst the 27 patients, DENV 1, 2, 3, and 4
were found in 13, 4, 7, and 3 of the patients, respectively. Of the 27,
16 (59%) and 10 (37%) were found to have primary and secondary
infections, respectively.
4.3. Increased levels of plasma Gal-9 in the DENV infection
In the critical phase, plasma Gal-9 levels were a signiﬁcantly
elevated in the DENV infected patients compared to those with
non-dengue febrile illness and HCs (P < 0.0001, Kruskal–Wallis test,
Fig. 1A). The median plasma Gal-9 levels for DENV infected, non-
dengue febrile patients, and HCs were 1525, 616, and 196 pg/ml,
respectively. The increase in Gal-9 in DENV infected patients
was found to be apparently associated with disease severity
(1407 pg/ml in DF and 2464 pg/ml in DHF patients). Gal-9 levels in
the 4 genotypes were also elevated to a similar extent (Fig. 1B), and
to our knowledge, these levels appear to be amongst the highest
ever reported in humans.
During the recovery phase, Gal-9 levels signiﬁcantly declined
overall to a median of 1010 pg/ml in all patients, except in 6 with
DF. The median level of Gal-9 in patients with DF and DHF during
the recovery phase was  1002 pg/ml and 1126 pg/ml, respectively
(Fig. 1C).
4.4. Numerous cytokines and chemokines were elevated in DENV
infection and were associated with Gal-9 levelsWe measured 29 cytokines and chemokines using a multi-
plex bead assay in all 65 patients (both in the critical as well
as the recovery phase of infection) in comparison to 30 HCs. In
638 H. Chagan-Yasutan et al. / Journal of Clin
Fig. 2. Signiﬁcant changes in cytokine/chemokine and galectin-9 levels in DENV
infected patients. Median fold changes in galectin-9 and cytokine/chemokine levels
were calculated as: median of the critical phase from DENV infected patients/median
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he critical phases of DENV infection, we found that 16 cytokines
nd chemokines, signiﬁcantly changed compared to HCs, with the
evels of IL-10, IP-10, and IL-1 having the greatest increase in
elation to Gal-9 levels (Fig. 2). The levels of 2 growth factors,
EGF, and EGF declined. However, the median levels of other
3 cytokines and chemokines remained unchanged compared to
Cs. All cytokines and chemokines that were elevated in the crit-
cal phase decreased in the recovery phase with the exception of
otaxin, which remained persistently high. The levels of VEGF and
GF remained low even into the recovery phase of infection.
A stepwise discriminant analysis was used to differentiate
HF from DF patients, in order to ascertain whether Gal-9 is an
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ymphocyte, monocyte, neutrophil, RBC, Hg, Hct, and Plt were used as independent vari
bbreviations: mo,  monocyte; Hct, hematocrit; Plt, platelet count.ical Virology 58 (2013) 635– 640
independent variable in DENV infection. Speciﬁcally, DF/DHF
was set as a dependent variable, and Gal-9 and other
cytokine/chemokines were set as independent variables. The
result showed that eotaxin, Gal-9, IFN-2, and MCP-1 could detect
92% of DHF and 79.3% of DF, speciﬁcally (P < 0.01). Furthermore,
using multiple regression analysis, we found that during the
critical phase of infection, Gal-9 was  signiﬁcantly associated with
IL-1 (P < 0.05), IL-8 (P < 0.001), IP-10 (P < 0.01), and VEGF (P < 0.05)
(Fig. 3A), and during the recovery phase Gal-9 was signiﬁcantly
associated with EGF (P < 0.01), IL-10 (P < 0.05), IL-8 (P < 0.05), and
VEGF (P < 0.05) (Fig. 3B).
4.5. Association of plasma Gal-9 levels with clinical variables of
DENV infection
We  next assessed whether plasma Gal-9 levels were associated
with the hematological variables of DENV infection using multi-
ple regression analysis. In both the critical and recovery phases of
DENV infection, we  observed that Gal-9 levels were positively asso-
ciated with Hematocrit (Hct), and inversely associated with platelet
counts. Furthermore, monocyte and viral RNA copy numbers were
also associated with plasma Gal-9 levels (Fig. 3C and D).
5. Discussion
Our results reveal for the ﬁrst time the dynamic of Gal-9
release in acute DENV infection. During the critical phase of acute
DENV infection, plasma Gal-9 levels were markedly elevated com-
pared to those in non-dengue febrile illness and HCs. The levelslution of inﬂammation. We  identiﬁed all 4 DENV genotypes in this
cohort in line with that previously reported in the Philippines26
and demonstrated no preferential regulation of Gal-9 by
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enotype. Multiplex analysis showed 16 out of 29 cytokines and
hemokines were signiﬁcant different compared to HCs during the
ritical phase. Gal-9 and above cytokines and chemokines might
e released by activated macrophages and endothelial cells fol-
owing DENV infection. The Gal-9 levels were inversely correlated
ith monocyte percentages in patients with DENV infection. There-
ore, we assumed that monocytes migrate and attach to inﬂamed
ndothelial cells. Released Gal-9 may  further activate monocytes
n autocrine manner.27
Gal-9 levels were also associated with platelet counts and
ematocrit levels in both critical and recovery phases. As a fam-
ly, galectins serve as “danger signals” that exert their actions on
everal immune cell populations, including mast cells.28 The asso-
iation of Gal-9 with dengue virus titers in the present study results
upports this hypothesis. Further, the activation of mast cells is
mportant because these cells secrete histamine, which enhance
he permeability of endothelial cells. We  previously reported a
ossible association between Gal-9 and histamine release in an
llergic patient.16 However, other mast cell-derived mediators such
s VEGF, tryptase, and chymase have been reported to participate
n the development of DHF.29 In fact, Gal-9 levels were associated
ith VEGF and also with other macrophage derived inﬂammatory
olecules such as IL-8 and IP-10.
From our data, it is evident that DENV viral content could regu-
ate the profound increase in circulating Gal-9 levels and the diverse
ytokine and chemokine storm associated with Gal-9. Acute HIV,
nlike acute HCV or HBV, leads to a rapid cytokine storm.30 We  have
hown that Gal-9 levels are greatly elevated in acute HIV infection17
nd recently found it appears to be related to HIV virus titers (data
ot shown) suggesting similar mechanisms may  be occurring. In
he present study, we found that non-virus pathogenic agents can
pregulate Gal-9: patients with leptospirosis had elevated Gal-9
evels compared to those with HCs, although this elevation was  not
s high as that in patients with DENV or acute HIV. Further stud-
es investigating Gal-9 in various infectious diseases is necessary
o clarify the biological nature underlying the elevation of Gal-9 in
ENV infection.
The limitation of our study was the small number of patients
ith DENV and non-age matched HCs included in our study. The
recise role of Gal-9 in DENV infection requires a large-scale longi-
udinal study that includes patients with serious symptoms such as
engue shock syndrome. Taken together, the present study shows
hat plasma levels of Gal-9 appears to track DENV inﬂammatory
esponses and could serve as an important novel biomarker of acute
ENV infection and disease severity.
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